Workflow
Otezla® (apremilast)
icon
Search documents
AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS
Prnewswire· 2025-09-26 13:00
Accessibility StatementSkip Navigation THOUSAND OAKS, Calif., Sept. 26, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs. The planned investment will support increased drug production at the company's biologics manufacturing facility in Juncos and integrate innovative advanced technologies throughout the operations process. It is expected to create nearly 750 jobs, including construction roles and new highly ...
AMGEN INVESTING MORE THAN HALF A BILLION DOLLARS IN NEW, STATE-OF-THE-ART CENTER FOR SCIENCE AND INNOVATION AT U.S. GLOBAL HEADQUARTERS
Prnewswire· 2025-09-02 13:01
Core Viewpoint - Amgen plans to invest over $600 million in a new center for science and innovation at its headquarters in Thousand Oaks, California, which is expected to create hundreds of jobs in the U.S. [1][5] Investment and Economic Impact - The new center aims to enhance collaboration among researchers, engineers, and scientists to accelerate the discovery of next-generation therapeutics [2] - Amgen has invested more than $40 billion in manufacturing and R&D in the U.S. since the Tax Cuts and Jobs Act (TCJA) of 2017, including over $5 billion in direct capital expenditures [3] - The enactment of pro-growth tax policies has facilitated Amgen's ability to invest domestically in cutting-edge science and manufacturing [3] Company Commitment and Future Plans - The new center will empower scientists with advanced tools and a collaborative environment to drive scientific excellence [4] - Construction is expected to begin in Q3 2025, further building on Amgen's recent investments, including a $900 million expansion in Central Ohio and a $1 billion investment for a second manufacturing plant in North Carolina [5] Company Background and Recognition - Amgen has been a pioneer in the biotechnology industry for over 40 years, focusing on innovative medicines for serious diseases [6] - The company has received accolades such as being named one of the "World's Most Innovative Companies" and "America's Best Large Employers" [7]
AMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND
Prnewswire· 2025-08-01 20:01
Core Points - Amgen's Board of Directors declared a dividend of $2.38 per share for Q3 2025, payable on September 12, 2025, to stockholders of record as of August 22, 2025 [1] - Amgen is a leader in biotechnology, focusing on innovative medicines for serious diseases, with a strong pipeline targeting cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases [2] - The company has received multiple accolades, including being named one of the "World's Most Innovative Companies" and "America's Best Large Employers," and is part of the Dow Jones Industrial Average and Nasdaq-100 Index [3] Company Overview - Amgen has over 40 years of experience in the biotechnology industry and utilizes advanced technology and human genetic data to drive innovation [2] - The company is recognized for its commitment to research and development, maintaining a broad and deep pipeline of medicines [2] Recognition and Market Position - In 2024, Amgen was recognized by Fast Company and Forbes for its innovation and employer status, highlighting its strong market position [3] - As a component of major stock indices, Amgen is considered one of the largest and most innovative non-financial companies [3]
Amgen (AMGN) Earnings Call Presentation
2025-06-27 09:28
Efficacy of MariTide - MariTide demonstrated strong efficacy with up to approximately 20% average weight loss without a plateau at 52 weeks[9, 84] - Up to approximately 98% of patients without Type 2 diabetes lost ≥5% of their body weight[29] - Up to approximately 99% of patients with Type 2 diabetes lost ≥ 5% of their body weight[38] - In adults with obesity WITH Type 2 Diabetes, MariTide demonstrated an impressive up to approximately 17% average weight loss at 52 weeks without a weight loss plateau[35] Cardiometabolic Improvements - In adults with obesity WITH Type 2 Diabetes, MariTide 420 mg monthly resulted in a -22% change in HbA1c, -58 mg/dL in Glucose, -11 mmHg in Systolic blood pressure, -28% in Triglycerides, and -72% in hs-CRP from baseline to week 52[41] - In adults with obesity WITHOUT Type 2 Diabetes, pooled 420 MariTide dose arms resulted in - 11 mmHg in Systolic blood pressure, - 5% in LDL-C, - 19% in Triglycerides, and - 53% in hs-CRP from baseline to week 52[44] Tolerability and Dosing - With one-step dose escalation in the Phase 2 study, the vomiting incidence was reduced and the discontinuation rate due to GI AEs was low at 8%[51] - Dose escalation significantly improves tolerability without compromising weight loss efficacy[9, 84] - Two-step dose escalation in the Phase 1 Low Dose Initiation study further reduced vomiting incidence with no discontinuation due to GI AEs[51] - In the Phase 1 Low Dose Initiation study, the mean baseline weight was 1006 kg[70]
Amgen(AMGN) - 2025 Q1 - Earnings Call Presentation
2025-05-01 20:23
Q1 2025 Financial Performance - Total revenue increased by 9% year-over-year, reaching $8.149 billion[97] - Product sales increased by 11% year-over-year, totaling $7.873 billion[97] - Non-GAAP EPS increased by 24% year-over-year, reaching $4.90[97] - Research and development investment increased by 12% year-over-year, reaching $1.5 billion[9] - Free cash flow was $980 million in Q1 2025, compared to $459 million in Q1 2024[117] Product Performance Highlights - Repatha sales increased by 27% year-over-year, reaching $656 million, driven by 41% volume growth[12, 22] - EVENITY sales increased by 29% year-over-year, reaching $442 million, driven by volume growth[12, 22] - Prolia sales increased by 10% year-over-year, reaching $1.099 billion, driven by 13% volume growth[12, 22] - TEZSPIRE sales increased by 65% year-over-year, reaching $285 million, driven by volume growth[12, 32] - BLINCYTO sales increased by 52% year-over-year, reaching $370 million, primarily driven by volume growth[12, 37] - IMDELLTRA generated $81 million in sales in Q1 2025[12, 17, 37] Pipeline and Regulatory Updates - FDA approved UPLIZNA for the treatment of IgG4-RD in adult patients[9, 51] - Positive Phase 3 data from IMDELLTRA, UPLIZNA, and rocatinlimab[9] - Initiated multiple Phase 3 trials of MariTide and TEZSPIRE[9] - The company expects 2025 revenue to be in the range of $34.3 billion to $35.7 billion[101]
AMGEN ANNOUNCES $900 MILLION MANUFACTURING EXPANSION, CREATION OF 350 NEW JOBS IN OHIO
Prnewswire· 2025-04-25 16:47
Core Points - Amgen announced a $900 million expansion of its manufacturing facility in Ohio, increasing total investment in Central Ohio to over $1.4 billion and creating 750 jobs [1][2] - The expansion is part of Amgen's commitment to U.S. manufacturing and aims to enhance its global biomanufacturing network [2][4] - Since the Tax Cuts and Jobs Act of 2017, Amgen has invested nearly $5 billion in the U.S., generating an estimated $12 billion in additional economic output [3] Company Overview - Amgen has been a leader in biologic medicine manufacturing since 1988 and emphasizes innovation and access to medicines for patients worldwide [2][5] - The company has a strong pipeline targeting various diseases, including cancer and heart disease, and has received multiple accolades for its innovation and workplace environment [6] Economic Impact - Ohio's supportive business climate and skilled workforce have made it an attractive location for Amgen's investments, contributing to the state's economic development [3] - The expansion in Ohio follows a recent announcement of a $1 billion investment for a second manufacturing plant in Holly Springs, NC, indicating a broader strategy to enhance U.S. manufacturing capabilities [4]
AMGEN ANNOUNCES 2025 SECOND QUARTER DIVIDEND
Prnewswire· 2025-03-04 21:54
THOUSAND OAKS, Calif., March 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the second quarter of 2025. The dividend will be paid on June 6, 2025, to all stockholders of record as of the close of business on May 16, 2025.About Amgen   Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen h ...